Fighting Cancer with a Single Draw of Blood
Advancing precision cancer care for patients everywhere
The Promise of Liquid Biopsy
Lucence makes ultrasensitive and non-invasive liquid biopsy tests for cancer detection and treatment selection. Our flagship test, LiquidHALLMARK®️ is swift, simple, and sensitive.
Powered by our proprietary technology, LiquidHALLMARK covers a wide range of clinically relevant biomarkers, including somatic mutations in 80 genes and fusions in 10 genes, across 15 cancer types.
LiquidHALLMARK provides deep insights into a patient’s cancer, including cancer-driving gene mutations and viruses, from a single blood draw for less invasive precision cancer care.
AmpliMark™:
A Paradigm Shift in
Precision Oncology
Our amplicon-based sequencing technology uses a unique molecular barcoding system to achieve error correction. This improves detection accuracy and sensitivity for multiple mutation types. AmpliMark is the foundational breakthrough technology in all of our liquid biopsy tests.
Learn more about AmpliMark